Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: The oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes

Drug Metabolism and Disposition

Volumn 43, Issue 5, 2015, Pages 646-659

  Meng, Jian ^a   Zhong, Dafang ^a   Li, Liang ^a   Yuan, Zhengyu ^b   Yuan, Hong ^b   Xie, Cen ^a   Zhou, Jialan ^a   Li, Chen ^a   Gordeev, Mikhail Fedorovich ^c   Liu, Jinqian ^c   Chen, Xiaoyan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b MicuRx Pharmaceuticals Inc   (China)

^c MicuRx Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(ISOXAZOL 3 YLAMINO)METHYL] 3 [2,3,5 TRIFLUORO 4 (4 OXO 2,3 DIHYDROPYRIDIN 1 YL)PHENYL]OXAZOLIDIN 2 ONE; ALDEHYDE DEHYDROGENASE; ALDEHYDE KETONE REDUCTASE; ANTIBIOTIC AGENT; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; FLAVIN CONTAINING MONOOXYGENASE 5; MRX 343; MRX 357; MRX 401; MRX 407; MRX 413; MRX 427; MRX 445 1; MRX 445 2; MRX 459; OXIDOREDUCTASE; UNCLASSIFIED DRUG; 2-(3,4-DIHYDRO-2H-PYRROLIUM-1-YL)-3-OXOINDAN-1-OLATE; 5-((ISOXAZOL-3-YLAMINO)METHYL)-3-(2,3,5-TRIFLUORO-4-(4-OXO-3,4-DIHYDROPYRIDIN-1(2H)-YL)PHENYL)OXAZOLIDIN-2-ONE; ANTIINFECTIVE AGENT; CYTOCHROME P450; INDAN DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; TAUTOMER; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CATALYSIS; CHEMISTRY; ENZYMOLOGY; FECES; LIVER; LIVER MICROSOME; METABOLISM; OXIDATION REDUCTION REACTION;

ANTI-BACTERIAL AGENTS; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; FECES; HUMANS; INDANS; LIVER; MALE; MICROSOMES, LIVER; OXAZOLIDINONES; OXIDATION-REDUCTION; PYRIDONES; PYRROLES;

EID: 84940387006     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061747     Document Type: Article

References (17)

1. Cashman JR (2008) Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 4:1507-1521.
2. Gordeev MF and Yuan ZY (2014) New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem 57:4487-4497.
3. Krafft GA and Katzenellenbogen JA (1981) Synthesis of halo enol lactones. Mechanism-based inactivators of serine proteases. J Am Chem Soc 103:5459-5466.
4. Lai WG, Farah N, Moniz GA, and Wong YN (2011) A Baeyer-Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61-70.
5. Li CR, Zhai QQ, Wang XK, Hu XX, Li GQ, Zhang WX, Pang J, Lu X, Yuan H, and Gordeev MF, et al. (2014) In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother 58:2418-2421.
6. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, and Rush R, et al. (2012) The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 40:1834-1845.
7. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
8. Rosemond MJC and Walsh JS (2004) Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335-361.
9. Shinabarger D (1999) Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 8:1195-1202.
10. Shono T, Matsumura Y, Hibino K, and Miyawaki S (1974) A novel synthesis of 1-citronellol from 1-menthone. Tetrahedron Lett 15:1295-1298.
11. Stagos D, Chen Y, Brocker C, Donald E, Jackson BC, Orlicky DJ, Thompson DC, and Vasiliou V (2010) Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial acetaldehyde-metabolizing enzyme. Drug Metab Dispos 38:1679-1687.
12. Strolin Benedetti M, Whomsley R, and Baltes E (2006) Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2:895-921.
13. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, and Bartlett JG Antimicrobial Availability Task Force of the Infectious Diseases Society of America (2006) Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-668.
14. Uetrecht JP and Trager W (2007) Drug Metabolism: Chemical and Enzymetic Aspects, p 61, Informa Healthcare, New York.
15. Vinh DC and Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59 (Suppl 1): S59-S74.
16. Verhoeven CH, Krebbers SF, Wagenaars GN, Booy CJ, Groothuis GM, Olinga P, and Vos RM (1998) In vitro and in vivo metabolism of the progestagen Org 30659 in several species. Drug Metab Dispos 26:1102-1112.
17. Zhang J and Cashman JR (2006) Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 34:19-26